Drug-Price Transparency in Communications Act
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Jul 26, 2018)
Drug-Price Transparency in Communications Act
This bill amends the Federal Food, Drug, and Cosmetic Act to impose a civil penalty on any person who disseminates a direct-to-consumer drug advertisement that does not include the wholesale acquisition cost (the manufacturer's list price to wholesalers or direct purchasers) for a 30-day supply of the drug.
The bill requires any representative of a drug manufacturer who communicates with a health care practitioner about a drug manufactured by the drug manufacturer to disclose the wholesale acquisition cost for a 30-day supply of the drug.
What just happenedJul 27, 2018
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseJul 26, 2018
- Jul 27, 2018Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Jul 26, 2018IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Jul 26, 2018IntroReferralIntro-H
Introduced in House
- Jul 26, 2018IntroReferral1000
Introduced in House